BTK and B-cell chronic lymphocytic leukemia: A direct comparison with other BTK inhibitors in WM has not yet been performed [32], although a randomized trial comparing acalabrutinib (n = 268) to ibrutinib (n = 265) in patients with R/R CLL showed that acalabrutinib had a better adverse effect profile than ibrutinib [33].